S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A trial deciding if JetBlue can buy Spirit — and further consolidate the industry — nears its end
GitLab is developing an AI-powered market reversal 
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A trial deciding if JetBlue can buy Spirit — and further consolidate the industry — nears its end
GitLab is developing an AI-powered market reversal 
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A trial deciding if JetBlue can buy Spirit — and further consolidate the industry — nears its end
GitLab is developing an AI-powered market reversal 
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A trial deciding if JetBlue can buy Spirit — and further consolidate the industry — nears its end
GitLab is developing an AI-powered market reversal 

Inari Medical Stock Price, News & Analysis (NASDAQ:NARI)

$62.15
-0.62 (-0.99%)
(As of 12/5/2023 ET)
Compare
Today's Range
$60.50
$62.99
50-Day Range
$48.30
$68.06
52-Week Range
$47.81
$73.10
Volume
577,386 shs
Average Volume
795,760 shs
Market Capitalization
$3.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$82.00

Inari Medical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
31.9% Upside
$82.00 Price Target
Short Interest
Bearish
9.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Inari Medical in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$9.56 M Sold Last Quarter
Proj. Earnings Growth
-87.50%
From $0.08 to $0.01 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

692nd out of 948 stocks

Medical Devices Industry

13th out of 17 stocks


NARI stock logo

About Inari Medical Stock (NASDAQ:NARI)

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy systems for the specific disease states in the United States. The company provides ClotTriever, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

NARI Stock Price History

NARI Stock News Headlines

After blowout earnings, Integer may be headed to new highs (NARI)
A growth strategy that includes both in-house expansion and acquisition activity could keep Integer Holdings Corporation's run going well into 2024.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Inari Medical Inc Ordinary Shares
Bill Hoffman Joins Magenta Medical's Board of Directors
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Inari Medical Closes Acquisition of LimFlow
Inari Medical: Top Buy For End Of 2023 And 2024
Q3 2023 Inari Medical Inc Earnings Call
Inari Medical to Acquire LimFlow for $250M
See More Headlines
Receive NARI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inari Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024

Industry, Sector and Symbol

Industry
Medical Devices
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NARI
Fax
N/A
Employees
1,100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$82.00
High Stock Price Target
$100.00
Low Stock Price Target
$65.00
Potential Upside/Downside
+31.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-29,270,000.00
Pretax Margin
0.56%

Debt

Sales & Book Value

Annual Sales
$469.31 million
Book Value
$7.77 per share

Miscellaneous

Free Float
49,700,000
Market Cap
$3.58 billion
Optionable
Not Optionable
Beta
0.92
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives















NARI Stock Analysis - Frequently Asked Questions

Should I buy or sell Inari Medical stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NARI shares.
View NARI analyst ratings
or view top-rated stocks.

What is Inari Medical's stock price target for 2024?

5 analysts have issued 1 year price targets for Inari Medical's shares. Their NARI share price targets range from $65.00 to $100.00. On average, they predict the company's share price to reach $82.00 in the next twelve months. This suggests a possible upside of 31.9% from the stock's current price.
View analysts price targets for NARI
or view top-rated stocks among Wall Street analysts.

How have NARI shares performed in 2023?

Inari Medical's stock was trading at $63.56 at the beginning of the year. Since then, NARI stock has decreased by 2.2% and is now trading at $62.15.
View the best growth stocks for 2023 here
.

When is Inari Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our NARI earnings forecast
.

How were Inari Medical's earnings last quarter?

Inari Medical, Inc. (NASDAQ:NARI) released its quarterly earnings results on Wednesday, November, 1st. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.00 by $0.05. The firm earned $126.37 million during the quarter, compared to analysts' expectations of $121.92 million. Inari Medical had a negative trailing twelve-month return on equity of 0.64% and a negative net margin of 0.59%. The business's revenue was up 31.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.19) EPS.

What other stocks do shareholders of Inari Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inari Medical investors own include NVIDIA (NVDA), Home Depot (HD), CVS Health (CVS), QUALCOMM (QCOM), Thermo Fisher Scientific (TMO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Procter & Gamble (PG) and Bristol-Myers Squibb (BMY).

When did Inari Medical IPO?

(NARI) raised $110 million in an IPO on Friday, May 22nd 2020. The company issued 7,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers.

Who are Inari Medical's major shareholders?

Inari Medical's stock is owned by a number of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (8.85%), Brown Advisory Inc. (2.52%), JPMorgan Chase & Co. (2.35%), Morgan Stanley (1.57%), Allspring Global Investments Holdings LLC (1.31%) and Northern Trust Corp (1.14%). Insiders that own company stock include Andrew Hykes, Ansbert Gadicke, Donald B Milder, Gilde Healthcare Cooperatieve, Kirk G Nielsen, Mitch C Hill, Mitch C Hill, Stanley Tang, Thomas Tu and William Hoffman.
View institutional ownership trends
.

How do I buy shares of Inari Medical?

Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NARI) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -